New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AstraZeneca PLC

AZN

Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.

Revenue
+6.70%
EPS
+23.5%
Free cash flow
+1.99%
Total debt
+1.75%

Quarter to September 2026, against a year earlier

175.60 0.15 +0.09%
Market cap
$272.1B
P/E
24.6×
Fwd P/E FY26e
24.2×
Dividend yield
1.83%
F-score
9/9
ROIC
12.3%
Net debt / EBITDA
1.1×
Payout ratio
0.5×

Revenue to profit Twelve months to Sep 30, 2026

Of every $100 of revenue, $21.32 was left as profit. Gross margin has risen two quarters running, from 81.7% to 81.9%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue62.4100.0%
Cost of revenue−11.3−18.1%
Gross profit51.181.9%
Research & development−15.3−24.5%
Selling, general & admin−21.8−34.9%
Other operating costs+0.71.2%
Operating income14.823.7%
Other income, net−1.5−2.4%
Income tax−2.3−3.6%
Other items+2.33.6%
Net income13.321.3%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$58.7B$60.4B$61.4B$62.4B
Operating income$13.7B$14.3B$14.0B$14.8B
Net income$12.4B$12.9B$12.6B$13.3B
Net margin (right axis)21.1%21.4%20.5%21.3%
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Revenue

+8 more TTM periods

58,739.00 60,439.00 61,366.00 62,384.00
Gross Profit
48,106.00 49,369.00 50,246.00 51,119.00
Operating Income
13,743.00 14,315.00 13,971.00 14,775.00
EBT
12,402.00 12,914.00 12,586.00 13,300.00
Income after Tax
10,233.00 10,393.00 10,453.00 11,034.00
Net Income Common
10,225.00 10,389.00 10,446.00 11,030.00
EPS (Diluted)
6.54 6.65 6.68 7.06
Shares (Diluted, Weighted)
1,562.00 1,562.00 1,562.25 1,562.00
Gross Margin
81.90% 81.68% 81.88% 81.94%
EBIT Margin
23.40% 23.69% 22.77% 23.68%
Net Profit Margin
17.41% 17.19% 17.02% 17.68%
Free Cash Flow Margin
15.01% 13.14% 10.21% 10.15%
EBITDA
19,476.00 20,130.00 20,326.00 21,186.00
EBIT
13,743.00 14,315.00 13,971.00 14,775.00

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026